Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - temazepam, quantity: 10 mg - tablet, uncoated - excipient ingredients: maize starch; lactose monohydrate; microcrystalline cellulose; magnesium stearate - adjunctive therapy for the short term management of insomnia in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - flunitrazepam, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; pregelatinised maize starch; magnesium stearate; indigo carmine; titanium dioxide; hypromellose; brilliant blue fcf; sunset yellow fcf; quinoline yellow; macrogol 4000 - severe cases of insomnia

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - temazepam, quantity: 10 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; maize starch; magnesium stearate - adjunctive therapy for the short term management of insomnia in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - temazepam, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; microcrystalline cellulose; magnesium stearate - adjunctive therapy for the short term management of insomnia in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - zopiclone, quantity: 7.5 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; purified talc; povidone; maize starch; sodium starch glycollate type a; hypromellose; lactose monohydrate; titanium dioxide; calcium hydrogen phosphate dihydrate; macrogol 6000 - short term treatment of insomnia (7 to 14 days)

Israel - English - Ministry of Health

neurim pharmaceuticals (1991) ltd, israel - melatonin - tablets prolonged release - melatonin 2 mg - melatonin - short-term treatment for primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.

Australia - English - Department of Health (Therapeutic Goods Administration)

rad data australia pty ltd - melatonin, quantity: 5 mg - tablet, modified release - excipient ingredients: ammonio methacrylate copolymer; calcium hydrogen phosphate dihydrate; lactose monohydrate; colloidal anhydrous silica; magnesium stearate; titanium dioxide; glucose monohydrate; maltodextrin; iron oxide yellow; lecithin; carmellose sodium - slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (asd) and / or smith-magenis syndrome, where sleep hygiene measures have been insufficient.

Australia - English - Department of Health (Therapeutic Goods Administration)

rad data australia pty ltd - melatonin, quantity: 1 mg - tablet, modified release - excipient ingredients: ammonio methacrylate copolymer; calcium hydrogen phosphate dihydrate; lactose monohydrate; colloidal anhydrous silica; purified talc; magnesium stearate; titanium dioxide; glucose monohydrate; maltodextrin; iron oxide yellow; iron oxide red; lecithin; carmellose sodium - slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (asd) and / or smith-magenis syndrome, where sleep hygiene measures have been insufficient.

Australia - English - Department of Health (Therapeutic Goods Administration)

arovella therapeutics ltd - zolpidem tartrate, quantity: 5 mg/actuation - spray, solution - excipient ingredients: benzoic acid; citric acid monohydrate; dilute hydrochloric acid; neotame; propylene glycol; purified water; flavour - zolpimist is indicated for the short term treatment of insomnia in adults (see section 4.2 dose and method of administration)

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - melatonin, quantity: 2 mg - tablet, modified release - excipient ingredients: lactose monohydrate; magnesium stearate; purified talc; colloidal anhydrous silica; ammonio methacrylate copolymer; calcium hydrogen phosphate dihydrate - monotherapy for the short term treatment of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.